Compare MARA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MARA | CRSP |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.9B |
| IPO Year | 2010 | 2016 |
| Metric | MARA | CRSP |
|---|---|---|
| Price | $13.23 | $62.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $17.85 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 40.5M | 1.5M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,093,000.00 | $289,590,000.00 |
| Revenue This Year | N/A | $807.72 |
| Revenue Next Year | $13.31 | $172.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 38.20 | ★ 9169.85 |
| 52 Week Low | $6.66 | $44.12 |
| 52 Week High | $23.45 | $78.48 |
| Indicator | MARA | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 69.76 |
| Support Level | $11.68 | $47.48 |
| Resistance Level | $13.80 | $75.06 |
| Average True Range (ATR) | 1.28 | 3.09 |
| MACD | -0.22 | 0.82 |
| Stochastic Oscillator | 29.78 | 90.86 |
MARA Holdings Inc leverages digital asset computing to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for Bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.